The annual risk of transformation of FL is 3% continuing without plateau beyond 15 years. Advanced stage at diagnosis is predictive of future transformation. Clinically diagnosed transformation has an equal impact on outcome as biopsy proven transformation.

Previous studies of follicular lymphoma (FL) patients treated heterogeneously have suggested that decreased numbers of regulatory T cells correlates with improved survival. We studied advancedstage FL patients from a single institution phase 2 trial. All patients were treated uniformly with multiagent chemotherapy and radiation. Tissue microarrays were constructed using diagnostic biopsies available in 105 patients and stained with CD4, CD8, CD25, and forkhead/winged helix transcription factor 3 (FOXP3) antibodies. Both cell content and cell distribution were evaluated. For all antibodies, there were cases with a predominant intrafollicular or perifollicular localization of cells (follicular pattern) while others displayed a diffuse pattern. The median follow-up of living patients was 17.1 years. The International Prognostic Index score predicted overall survival (OS; P ‫؍‬ .004) but not risk of transformation (RT). Cell content did not impact survival, while immunoarchitectural patterns of CD4/ CD8 were significant for progression-free survival (PFS; P ‫؍‬ .056), CD25 for both PFS and OS (P ‫؍‬ .002 and P ‫؍‬ .024, respectively), and FOXP3 ؉ predicted PFS, OS, and RT (P ‫؍‬ .001, P < .001 and p ‫؍‬ .002, respectively). A Cox multivariate model showed both International Prognostic Index score and FOXP3 ؉ pattern were independent predictors of OS (P ‫؍‬ .008 and P < .001, respectively), while only FOXP3 ؉ pattern predicted RT (P ‫؍‬ .004). We conclude that FOXP3 ؉ cell distribution significantly predicts survival and RT in FL. (Blood. 2010;115: 289-295)

The secondary genetic events associated with follicular lymphoma (FL) progression are not well defined. We applied genome-wide BAC array comparative genomic hybridization to 106 diagnostic biopsies of FL to characterize regional genomic imbalances. Using

Patients undergoing autoSCT had better outcomes than those treated with rituximab-containing chemotherapy alone. AlloSCT did not improve outcome compared with rituximab-containing chemotherapy and was associated with clinically significant toxicity.